TY  - JOUR
AU  - Steelman, Linda S
AU  - Fitzgerald, Timothy
AU  - Lertpiriyapong, Kvin
AU  - Cocco, Lucio
AU  - Follo, Matilde Y
AU  - Martelli, Alberto M
AU  - Neri, Luca M
AU  - Marmiroli, Sandra
AU  - Libra, Massimo
AU  - Candido, Saverio
AU  - Nicoletti, Ferdinando
AU  - Scalisi, Aurora
AU  - Fenga, Concettina
AU  - Drobot, Lyudmyla
AU  - Rakus, Dariusz
AU  - Gizak,  Agnieszka
AU  - Laidler, Piotr
AU  - Dulinska-Litewka, Joanna
AU  - Basecke,  Joerg
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Montalto, Giuseppe
AU  - Cervello, Melchiorre
AU  - Milella, Michelle
AU  - Tafuri, Agustino
AU  - Demidenko, Zoya
AU  - Abrams,  Stephen L
AU  - McCubrey, James A
PY  - 2016
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/3822
AB  - The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980's. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.
PB  - Sharjah: Bentham Science Publishers
T2  - Current Pharmaceutical Design
T1  - Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
IS  - 16
VL  - 22
DO  - 10.2174/1381612822666160304151011
SP  - 2358
EP  - 2388
ER  - 

@article{
author = "Steelman, Linda S and Fitzgerald, Timothy and Lertpiriyapong, Kvin and Cocco, Lucio and Follo, Matilde Y and Martelli, Alberto M and Neri, Luca M and Marmiroli, Sandra and Libra, Massimo and Candido, Saverio and Nicoletti, Ferdinando and Scalisi, Aurora and Fenga, Concettina and Drobot, Lyudmyla and Rakus, Dariusz and Gizak,  Agnieszka and Laidler, Piotr and Dulinska-Litewka, Joanna and Basecke,  Joerg and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Montalto, Giuseppe and Cervello, Melchiorre and Milella, Michelle and Tafuri, Agustino and Demidenko, Zoya and Abrams,  Stephen L and McCubrey, James A",
year = "2016",
abstract = "The roles of the epidermal growth factor receptor (EGFR) signaling pathway in various cancers including breast, bladder, brain, colorectal, esophageal, gastric, head and neck, hepatocellular, lung, neuroblastoma, ovarian, pancreatic, prostate, renal and other cancers have been keenly investigated since the 1980's. While the receptors and many downstream signaling molecules have been identified and characterized, there is still much to learn about this pathway and how its deregulation can lead to cancer and how it may be differentially regulated in various cell types. Multiple inhibitors to EGFR family members have been developed and many are in clinical use. Current research often focuses on their roles and other associated pathways in cancer stem cells (CSCs), identifying sites where therapeutic resistance may develop and the mechanisms by which microRNAs (miRs) and other RNAs regulate this pathway. This review will focus on recent advances in these fields with a specific focus on breast cancer and breast CSCs. Relatively novel areas of investigation, such as treatments for other diseases (e.g., diabetes, metabolism, and intestinal parasites), have provided new information about therapeutic resistance and CSCs.",
publisher = "Sharjah: Bentham Science Publishers",
journal = "Current Pharmaceutical Design",
title = "Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy",
number = "16",
volume = "22",
doi = "10.2174/1381612822666160304151011",
pages = "2358-2388"
}

Steelman, L. S., Fitzgerald, T., Lertpiriyapong, K., Cocco, L., Follo, M. Y., Martelli, A. M., Neri, L. M., Marmiroli, S., Libra, M., Candido, S., Nicoletti, F., Scalisi, A., Fenga, C., Drobot, L., Rakus, D., Gizak,  ., Laidler, P., Dulinska-Litewka, J., Basecke,  ., Mijatović, S., Maksimović-Ivanić, D., Montalto, G., Cervello, M., Milella, M., Tafuri, A., Demidenko, Z., Abrams,  . L.,& McCubrey, J. A.. (2016). Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. in Current Pharmaceutical Design
Sharjah: Bentham Science Publishers., 22(16), 2358-2388.
https://doi.org/10.2174/1381612822666160304151011

Steelman LS, Fitzgerald T, Lertpiriyapong K, Cocco L, Follo MY, Martelli AM, Neri LM, Marmiroli S, Libra M, Candido S, Nicoletti F, Scalisi A, Fenga C, Drobot L, Rakus D, Gizak  , Laidler P, Dulinska-Litewka J, Basecke  , Mijatović S, Maksimović-Ivanić D, Montalto G, Cervello M, Milella M, Tafuri A, Demidenko Z, Abrams  L, McCubrey JA. Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy. in Current Pharmaceutical Design. 2016;22(16):2358-2388.
doi:10.2174/1381612822666160304151011 .

Steelman, Linda S, Fitzgerald, Timothy, Lertpiriyapong, Kvin, Cocco, Lucio, Follo, Matilde Y, Martelli, Alberto M, Neri, Luca M, Marmiroli, Sandra, Libra, Massimo, Candido, Saverio, Nicoletti, Ferdinando, Scalisi, Aurora, Fenga, Concettina, Drobot, Lyudmyla, Rakus, Dariusz, Gizak,  Agnieszka, Laidler, Piotr, Dulinska-Litewka, Joanna, Basecke,  Joerg, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Montalto, Giuseppe, Cervello, Melchiorre, Milella, Michelle, Tafuri, Agustino, Demidenko, Zoya, Abrams,  Stephen L, McCubrey, James A, "Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy" in Current Pharmaceutical Design, 22, no. 16 (2016):2358-2388,
https://doi.org/10.2174/1381612822666160304151011 . .

TY  - JOUR
AU  - Davis, Nicole M.
AU  - Sokolosky, Melissa
AU  - Stadelman, Kristin
AU  - Abrams, Stephen L.
AU  - Libra, Massimo
AU  - Candido, Saverio
AU  - Nicoletti, Ferdinando
AU  - Polesel, Jerry
AU  - Maestro, Roberta
AU  - D'Assoro, Antonino
AU  - Drobot, Lyudmyla
AU  - Rakus, Dariusz
AU  - Gizak, Agnieszka
AU  - Laidler, Piotr
AU  - Dulinska-Litewka, Joanna
AU  - Basecke, Joerg
AU  - Mijatović, Sanja
AU  - Maksimović-Ivanić, Danijela
AU  - Montalto, Giuseppe
AU  - Cervello, Melchiorre
AU  - Fitzgerald, Timothy L.
AU  - Demidenko, Zoya N.
AU  - Martelli, Alberto M.
AU  - Cocco, Lucio
AU  - Steelman, Linda S.
AU  - McCubrey, James A.
PY  - 2014
UR  - https://radar.ibiss.bg.ac.rs/handle/123456789/2188
AB  - The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in
   malignant transformation, prevention of apoptosis, drug resistance and
   metastasis. The expression of this pathway is frequently altered in
   breast cancer due to mutations at or aberrant expression of: HER2,
   ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, TP53, RB as well as other
   oncogenes and tumor suppressor genes. In some breast cancer cases,
   mutations at certain components of this pathway (e.g., PIK3CA) are
   associated with a better prognosis than breast cancers lacking these
   mutations. The expression of this pathway and upstream HER2 has been
   associated with breast cancer initiating cells (CICs) and in some cases
   resistance to treatment. The anti-diabetes drug metformin can suppress
   the growth of breast CICs and herceptin-resistant HER2+ cells. This
   review will discuss the importance of the
   EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway primarily in breast cancer but
   will also include relevant examples from other cancer types. The
   targeting of this pathway will be discussed as well as clinical trials
   with novel small molecule inhibitors. The targeting of the hormone
   receptor, HER2 and EGFR1 in breast cancer will be reviewed in
   association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3
   pathway.
T2  - Oncotarget
T1  - Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer:
 possibilities for therapeutic intervention
IS  - 13
VL  - 5
DO  - 10.18632/oncotarget.2209
SP  - 4603
EP  - 4650
ER  - 

@article{
author = "Davis, Nicole M. and Sokolosky, Melissa and Stadelman, Kristin and Abrams, Stephen L. and Libra, Massimo and Candido, Saverio and Nicoletti, Ferdinando and Polesel, Jerry and Maestro, Roberta and D'Assoro, Antonino and Drobot, Lyudmyla and Rakus, Dariusz and Gizak, Agnieszka and Laidler, Piotr and Dulinska-Litewka, Joanna and Basecke, Joerg and Mijatović, Sanja and Maksimović-Ivanić, Danijela and Montalto, Giuseppe and Cervello, Melchiorre and Fitzgerald, Timothy L. and Demidenko, Zoya N. and Martelli, Alberto M. and Cocco, Lucio and Steelman, Linda S. and McCubrey, James A.",
year = "2014",
abstract = "The EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway plays prominent roles in
   malignant transformation, prevention of apoptosis, drug resistance and
   metastasis. The expression of this pathway is frequently altered in
   breast cancer due to mutations at or aberrant expression of: HER2,
   ERalpha, BRCA1, BRCA2, EGFR1, PIK3CA, PTEN, TP53, RB as well as other
   oncogenes and tumor suppressor genes. In some breast cancer cases,
   mutations at certain components of this pathway (e.g., PIK3CA) are
   associated with a better prognosis than breast cancers lacking these
   mutations. The expression of this pathway and upstream HER2 has been
   associated with breast cancer initiating cells (CICs) and in some cases
   resistance to treatment. The anti-diabetes drug metformin can suppress
   the growth of breast CICs and herceptin-resistant HER2+ cells. This
   review will discuss the importance of the
   EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3 pathway primarily in breast cancer but
   will also include relevant examples from other cancer types. The
   targeting of this pathway will be discussed as well as clinical trials
   with novel small molecule inhibitors. The targeting of the hormone
   receptor, HER2 and EGFR1 in breast cancer will be reviewed in
   association with suppression of the EGFR/PI3K/PTEN/Akt/mTORC1/GSK-3
   pathway.",
journal = "Oncotarget",
title = "Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer:
 possibilities for therapeutic intervention",
number = "13",
volume = "5",
doi = "10.18632/oncotarget.2209",
pages = "4603-4650"
}

Davis, N. M., Sokolosky, M., Stadelman, K., Abrams, S. L., Libra, M., Candido, S., Nicoletti, F., Polesel, J., Maestro, R., D'Assoro, A., Drobot, L., Rakus, D., Gizak, A., Laidler, P., Dulinska-Litewka, J., Basecke, J., Mijatović, S., Maksimović-Ivanić, D., Montalto, G., Cervello, M., Fitzgerald, T. L., Demidenko, Z. N., Martelli, A. M., Cocco, L., Steelman, L. S.,& McCubrey, J. A.. (2014). Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer:
 possibilities for therapeutic intervention. in Oncotarget, 5(13), 4603-4650.
https://doi.org/10.18632/oncotarget.2209

Davis NM, Sokolosky M, Stadelman K, Abrams SL, Libra M, Candido S, Nicoletti F, Polesel J, Maestro R, D'Assoro A, Drobot L, Rakus D, Gizak A, Laidler P, Dulinska-Litewka J, Basecke J, Mijatović S, Maksimović-Ivanić D, Montalto G, Cervello M, Fitzgerald TL, Demidenko ZN, Martelli AM, Cocco L, Steelman LS, McCubrey JA. Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer:
 possibilities for therapeutic intervention. in Oncotarget. 2014;5(13):4603-4650.
doi:10.18632/oncotarget.2209 .

Davis, Nicole M., Sokolosky, Melissa, Stadelman, Kristin, Abrams, Stephen L., Libra, Massimo, Candido, Saverio, Nicoletti, Ferdinando, Polesel, Jerry, Maestro, Roberta, D'Assoro, Antonino, Drobot, Lyudmyla, Rakus, Dariusz, Gizak, Agnieszka, Laidler, Piotr, Dulinska-Litewka, Joanna, Basecke, Joerg, Mijatović, Sanja, Maksimović-Ivanić, Danijela, Montalto, Giuseppe, Cervello, Melchiorre, Fitzgerald, Timothy L., Demidenko, Zoya N., Martelli, Alberto M., Cocco, Lucio, Steelman, Linda S., McCubrey, James A., "Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer:
 possibilities for therapeutic intervention" in Oncotarget, 5, no. 13 (2014):4603-4650,
https://doi.org/10.18632/oncotarget.2209 . .